News & Updates

Use of anlotinib combined with etoposide and carboplatin (EC; chemotherapy) as first-line therapy for patients with extensive-stage small cell lung cancer (ES-SCLC) yields a significantly improved progression-free survival (PFS) as well as overall survival (OS) benefits when compared with chemotherapy, according to data from the phase III ETER701 trial presented at ELCC 2024.

Patients with familial pulmonary fibrosis (FPF) share an equally aggressive disease progression as those with sporadic idiopathic pulmonary fibrosis (IPF) even though they are younger and less exposed to tobacco, reveals a study.

Post-exposure prophylaxis with the probiotic Lacticaseibacillus rhamnosus GG (LGG) led to prolonged time to COVID-19 infection, reduced incidence of symptoms, and gut microbiome changes, but not overall incidence, a study suggests.

Adding the anti-interleukin-4 receptor alpha monoclonal antibody dupilumab to an inhaled corticosteroid (ICS) reduces asthma exacerbations and improves lung function in a post hoc analysis of the LIBERTY ASTHMA QUEST trial.